Neoadjuvant Chemoimmunotherapy for Small Cell Carcinoma of the Esophagus: Clinical Efficacy and Biomarker Exploration

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 Jul 5

PMID 38967227

Authors

Junhan Wu

Xin Xia

Longlong Gong

Shujie Huang

Hongbo Zheng

Guibin Qiao

Yong Tang

Affiliations

Soon will be listed here.

Abstract

Small cell carcinoma of the esophagus (SCCE) is a rare and highly malignant type of esophageal cancer with no standard treatment, facing challenges of resistance to conventional therapies. This study presents the cases of one extensive-stage and two limited-stage SCCE patients treated with chemoimmunotherapy. The two limited-stage patients underwent surgery post-treatment and experienced notable and enduring positive responses. This represents the first documented application of neoadjuvant chemoimmunotherapy in limited-stage SCCE patients. Additionally, comprehensive immunohistochemical analysis and whole exome sequencing were performed on the case patients. The findings revealed that infiltration of CD8 T cells and PD-L1 expression in the SCCE tumor were key factors for favorable responses in SCCE patients receiving chemoimmunotherapy.

Citing Articles

Single-cell RNA sequencing elucidates cellular plasticity in esophageal small cell carcinoma following chemotherapy treatment.

Zhang Q, Gao Z, Qiu R, Cao J, Zhang C, Qin W Front Genet. 2025; 15():1477705.

PMID: 39850495 PMC: 11754407. DOI: 10.3389/fgene.2024.1477705.

Novel FABP4C1q macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis.

Zhang D, Wang M, Liu G, Li X, Yu W, Hui Z Cell Death Dis. 2024; 15(10):717.

PMID: 39353883 PMC: 11445384. DOI: 10.1038/s41419-024-07074-x.

References

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Wong A, Shao M, Rineer J, Osborn V, Schwartz D, Schreiber D . Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base. Dis Esophagus. 2016; 30(2):1-5. DOI: 10.1111/dote.12487. View

Ajani J, DAmico T, Bentrem D, Cooke D, Corvera C, Das P . Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(4):393-422. DOI: 10.6004/jnccn.2023.0019. View

Zhang C, Zhang G, Xue L, Zhang Z, Zeng Q, Wu P . Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8 + T-cell infiltration in small cell carcinoma of the esophagus: a retrospective analysis of 34 years of National Cancer Center data in China. Int J Surg. 2023; 110(7):4297-4309. PMC: 11254267. DOI: 10.1097/JS9.0000000000000064. View

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

Megyesfalvi Z, Gay C, Popper H, Pirker R, Ostoros G, Heeke S . Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023; 73(6):620-652. DOI: 10.3322/caac.21785. View

Rudin C, Poirier J, Byers L, Dive C, Dowlati A, George J . Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019; 19(5):289-297. PMC: 6538259. DOI: 10.1038/s41568-019-0133-9. View

Iams W, Porter J, Horn L . Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020; 17(5):300-312. PMC: 7212527. DOI: 10.1038/s41571-019-0316-z. View

Wang F, Liu D, Zhao Q, Chen G, Liu X, Wang Y . The genomic landscape of small cell carcinoma of the esophagus. Cell Res. 2018; 28(7):771-774. PMC: 6028429. DOI: 10.1038/s41422-018-0039-1. View

10.

Liu Y . Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol. 2023; 29(34):5020-5037. PMC: 10518742. DOI: 10.3748/wjg.v29.i34.5020. View

11.

Zhang Y, Liu X, Liang H, Liu W, Wang H, Li T . Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report. J Int Med Res. 2023; 51(7):3000605231187942. PMC: 10387792. DOI: 10.1177/03000605231187942. View

12.

Yamashita S, Abe H, Yamashita H, Yagi K, Seto Y, Ushiku T . PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma. Histopathology. 2023; 83(2):264-275. DOI: 10.1111/his.14924. View

13.

Li R, Yang Z, Shao F, Cheng H, Wen Y, Sun S . Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nat Commun. 2021; 12(1):3785. PMC: 8213753. DOI: 10.1038/s41467-021-24043-6. View

14.

Ilett E, Langer S, Olsen I, Federspiel B, Kjaer A, Knigge U . Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel). 2016; 5(2):119-76. PMC: 4665594. DOI: 10.3390/diagnostics5020119. View

15.

Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X . FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist. 2021; 26(5):433-438. PMC: 8100557. DOI: 10.1002/onco.13752. View

16.

Ishida H, Kasajima A, Kamei T, Miura T, Oka N, Yazdani S . SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis. Mod Pathol. 2017; 30(5):660-671. DOI: 10.1038/modpathol.2016.222. View

17.

Liu L, Liu Y, Gong L, Zhang M, Wu W . Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther. 2020; 21(11):983-989. PMC: 7678944. DOI: 10.1080/15384047.2020.1829265. View

18.

Verma V, Sleightholm R, Fang P, Ryckman J, Lin C . National Cancer Database report of nonmetastatic esophageal small cell carcinoma. Cancer Med. 2018; 7(12):6365-6373. PMC: 6308049. DOI: 10.1002/cam4.1712. View

19.

Shah M, Goldner W, Benson A, Bergsland E, Blaszkowsky L, Brock P . Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(7):839-868. DOI: 10.6004/jnccn.2021.0032. View

20.

Ren W, Wu P, Tian J, Chen D, Li S, Liu B . Anti-PD-1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer: A case report. Thorac Cancer. 2020; 12(2):264-267. PMC: 7812062. DOI: 10.1111/1759-7714.13735. View